Preoperative Low 25-hydroxyvitamin D Level Is Associated With Poor Prognosis of Papillary Thyroid Cancer

Munire Abuduwaitil
West China Hospital of Medicine: Sichuan University West China Hospital  https://orcid.org/0000-0002-1541-6143

Zhichao Xing
West China Hospital of Medicine: Sichuan University West China Hospital

Yuan Fei
West China Hospital of Medicine: Sichuan University West China Hospital

Baoying Xia
West China Hospital of Medicine: Sichuan University West China Hospital

Jingqiang Zhu
West China Hospital of Medicine: Sichuan University West China Hospital

Anping Su (✉ suanpingping@126.com )
West China Hospital of Medicine: Sichuan University West China Hospital  https://orcid.org/0000-0003-2289-9339

Keywords: 25-hydroxyvitamin D, Papillary thyroid cancer, Prognosis, Lymph node metastasis

DOI: https://doi.org/10.21203/rs.3.rs-727962/v1

License: ©️ ♂️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Preoperative low 25-hydroxyvitamin D level is associated with poor prognosis of papillary thyroid cancer

Munire Abuduwaili¹, Zhichao Xing, Yuan Fe, Baoying Xia, Jingqiang Zhu, Anping Su

Abstract

Purpose: To evaluate the relationship between preoperative 25-hydroxyvitamin D (25(OH)D) level and poor prognosis factors of papillary thyroid cancer. Methods: A total of 1198 patients diagnosed of papillary thyroid cancer were analyzed retrospectively. Patients were categorized into vitamin D deficiency (VDD) group and normal group according to preoperative 25(OH)D < 20 ng/mL and 25(OH)D ≥ 20 ng/mL. Differences of demographic data and clinicopathological characteristics were analyzed between two groups. Linear and logistic regression analysis to determine the effect of 25(OH)D on the established poor prognosis factors of papillary thyroid cancer were also applied. Results: We observed a negative linear correlation between 25(OH)D levels and tumor size and an independent relationship between VDD and lymph node metastasis in central area. Additionally, there was a significant correlation between preoperative 25(OH)D and thyroid-stimulating hormone (TSH) levels. Conclusions: 25(OH)D level significantly associated with certain poor prognosis factors of papillary thyroid cancer. Assessing and supplementing vitamin D may be an important addition to preoperative management of patients with papillary thyroid cancer.

Keywords: 25-hydroxyvitamin D, Papillary thyroid cancer, Prognosis, Lymph node metastasis

¹Center of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University, PR China.
²Correspondence: Anping Su, Center of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University, NO. 37 Guo Xue Xiang, Chengdu, Sichuan 610041, PR China (e-mail: suanpingping@126.com).
Declarations

Funding

No funding was received to assist with the preparation of this manuscript.

Conflicts of interest

The authors have no conflicts of interest to declare that are relevant to the content of this article.

Availability of data and material

Not applicable

Code availability

Not applicable

Authors’ contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Zhichao Xing, Baoying Xia and Munire Abuduwaili. The first draft of the manuscript was written by Munire Abuduwaili and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Ethics approval

Ethical approval was waived by the local Ethics Committee of West China Hospital, Sichuan University, in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable.
Acknowledgments

We thank director Jingqiang Zhu of Center of Thyroid and Parathyroid Surgery, West China Hospital for providing administrative support

Introduction

Vitamin D is a group of compounds, regulating the absorption of calcium, phosphates, and magnesium is its classic function. Additional function of vitamin D is to regulate the cellular life cycle and angiogenesis by certain signaling pathways. Numerous studies have demonstrated that vitamin D deficiency was related to various diseases including metabolic syndrome, hypertension, cardiovascular diseases and cancer. Besides, Vitamin D and its metabolites had been found to participate in the development and progression of cancers. In breast, colon, and prostate carcinoma, vitamin D have been recommended as a prognostic indicator.

Thyroid cancer is the most popular malignant tumor in endocrine-system, with incidence varying from 0.5 to 1.5%. Prognostic factors of thyroid cancer that have been established before including age, invasive pathological subtypes, tumor size, lymphovascular invasion, extra-capsular spread, and lymph nodal metastases. Compared with these factors that can’t be intervened before operation, it is more essential to determine the high-risk prognostic features that are easily modifiable. A relationship between vitamin D and thyroid diseases was highlighted recently. Low status of 25(OH) D was found to significantly relate to autoimmune thyroid diseases (AITD) and thyroid cancer. While the etiology is not clear, it may be related to inflammatory processes. However, a definitive correlation between vitamin D deficiency and poor prognosis in papillary thyroid carcinoma has never been demonstrated in a large number of patients.

Our study aimed to evaluate the relationship between preoperative 25(OH)D level and poor prognosis factors in papillary thyroid cancer, and to determine if vitamin D deficiency is able to predict poor prognosis of papillary thyroid carcinoma.

1. Material and Methods

In this study, we enrolled 1198 patients diagnosed as papillary thyroid cancer between June 2016 and Nov 2019 at the Department of Thyroid Surgery of West China Hospital. Clinicopathological characteristics, prognostic features and demographic data were retrospectively collected. Our research had been waived by the medical ethics committee of the institution.
At least unilateral lobectomy of thyroid and excision of thyroid isthmus was performed on all patients. Therapeutic neck dissection was performed only in cases that lymph node metastasis was confirmed by preoperative fine-needle aspiration biopsy (FNAB) or intraoperative pathologic section. Tumor size, confirmed by histopathology reports of patients, was defined as the greatest cancer diameter. AJCC/TNM staging system was applied in this study [13].

Serum 25(OH)D concentrations were measured the day before surgery. VDD was defined by 25(OH)D<20 ng/mL[14]. Patients were categorized into VDD group and normal group according to preoperative 25(OH)D <20 ng/mL and 25(OH)D≥20 ng/mL.

2. Statistical Analysis

We used SPSS 23.0 to process data and considered p-values <0.05 as statistically significant. Categorical variables were presented as absolute. Pearson’s χ²-test was used to examine the differences of categorical variables. Continuous variables were presented as median values because non-normal distribution. Differences of continuous variables were examined using Mann-Whitney U test. Spearman rank correlation test and Kendall’s tau correlation test was used to determine the correlations between age, sex, BMI, TgAb, Tg, TSH and 25(OH)D levels. Simple linear regression analysis was performed to demonstrate the correlation between tumor size and 25(OH)D level. We also applied univariate logistic regression analysis to determine the effect of VDD on the poor prognosis factors of papillary thyroid cancer. Multivariate logistic regression analysis for various prognostic factors in relation to VDD was also used to determine independent influencing factors.

3. Results

A total of 1198 patients were involved in the present analysis. The characteristics and comparison of the patients separated into two groups based on 25(OH)D level are noted in Table 1. Patients with VDD had higher TSH level than patients in normal group (2.87(1.97-3.96) VS 2.61(1.65-3.94), P = 0.028). The median age of patients with VDD was 39, compared to 47 in patients without VDD (p = 0.00). The proportion of females in VDD group was lower than normal group (76.33% vs 62.30%, p = 0.00). There was no significant difference between the two groups for BMI (body mass index), TgAb and Tg levels.
Table 1: Demographic of patients with papillary thyroid cancer

|                        | VDD group               | Normal group             | P   |
|------------------------|-------------------------|--------------------------|-----|
| Age (years)            | 39(31-48)               | 47(37-53.75)             | 0   |
| Female                 | 616(76.33%)             | 243(62.30%)              | 0   |
| BMI (kg/m$^2$)         | 22.72(20.56-25.29)      | 23.36(21.56-25.39)       | 0.184|
| TSH (mU/L)             | 2.87(1.97-3.96)         | 2.61(1.65-3.94)          | 0.028|
| TgAb (IU/mL)           | 15.73(10.26-119.90)     | 13.09(10-42.28)          | 0.31 |
| Tg (µg/L)              | 13.56(5.66-29.68)       | 12.07(6.74-25.42)        | 0.521|

Abbreviations: BMI = body mass index; TSH = thyroid-stimulating hormone; TgAb: anti-thyroglobulin antibodies; Tg: Thyroglobulin.

Clinicopathological characteristics among the two groups were analyzed (Table2). Histopathological features associated with poor prognosis were also documented. Positive results of multifocality, tumor size $\geq$1 cm, presence of extra-thyroid invasion, capsular invasion, BRAF mutation, stratification of the risk of recurrence and other characteristics did not significantly differ between the two groups. Diagnosis of lymph nodes metastasis and central lymph node metastasis between the two groups showed significant differences (P <0.05). Cancer stages also showed significant differences among the two groups(P=0.035). The median of tumor size was different between the two groups, but the differences were not statistically significant (9 vs 8, p=0.10).

Simple linear regression analysis was performed to demonstrate the correlation between tumor size and 25(OH)D level. As shown in Fig1, tumor size increased with decreased 25(OH)D level (Fig.1). The correlation was significant following adjustment for age, sex, BMI and TSH (r=-0.067, p = 0.049).

Correlations of 25(OH)D level with age, sex, BMI, TgAb, Tg and TSH levels were analyzed used Spearman rank correlation test and Kendall’s tau correlation test (Table 3). According to the preoperative laboratory examination results, increasing 25(OH)D was significantly associated with decreasing TSH and increasing age (OR=-0.078 P=0.007; OR=0.175 P=0; respectively). However, postoperative 25(OH)D level did not correlate with TSH level examined after operation. Besides, there was a significant sexual distinction in 25(OH)D level.
Table 2: Clinicopathological characteristics according to groups of 25-Hydroxyvitamin D levels

|                              | VDD group | Normal group | P   |
|------------------------------|-----------|--------------|-----|
| Tumor size (mm)              | 9(6-15)   | 8(6-11.75)   | 0.1 |
| Tumor size > 1 cm            | 201       | 80           | 0.093 |
| Multiplicity                 | 21        | 9            | 0.76 |
| Capsular invasion            | 506       | 234          | 0.367 |
| Extrathyroidal invasion      | 137       | 66           | 0.982 |
| Lymph node metastasis        | 516       | 222          | 0.019 |
| Central                      | 311       | 123          | 0.018 |
| Lateral                      | 205       | 99           | 0.995 |
| Multinodular goiter          | 358       | 160          | 0.275 |
| Hashimoto’s thyroiditis      | 118       | 54           | 0.72 |
| Risk of recurrence           |           |              |     |
| Low                          | 349       | 179          |     |
| Intermediate                 | 324       | 146          |     |
| High                         | 134       | 66           |     |
| Radioactive iodine therapy   | 338       | 153          | 0.382 |
| TNM                          |           |              |     |
| T1a/T1b/T2/T3a/T3b/T4        | 463/157/38/12/65/72 | 239/70/12/3/26/40 | 0.425 |
| N0/N1a/N1b                   | 291/311/205 | 168/124/99   | 0.036 |
| M1                           | 6         | 7            | 0.101 |
| Stage I / II / III-IV        | 732/57/18 | 337/45/9     | 0.035 |
| BRAFV600E mutation           | 149       | 81           | 0.353 |

Table 3: Correlations of 25-Hydroxyvitamin D levels with sex, age, BMI, TgAb, Tg and TSH levels

|                              | Before operation | After operation |
|------------------------------|------------------|----------------|
|                              | OR    | P   | OR      | P      |
| Sex                          | -0.131 | 0   | -0.999 | 0      |
| Age                          | 0.175  | 0   | 0.171  | 0      |
| BMI                          | 0.045  | 0.132 | -0.011 | 0.749  |
| TSH                          | -0.078 | 0.007 | 0.023  | 0.483  |
| TgAb                         | -0.006 | 0.848 | -0.004 | 0.896  |
| Tg                           | -0.028 | 0.462 | 0.036  | 0.29   |
Table 4: Univariate logistic regression analysis of the effect of vitamin D deficiency on the aggressiveness of papillary thyroid cancer

|                                | P  | OR   | CI       |
|--------------------------------|----|------|----------|
| T3/4                           |    |      |          |
| Model 1                        | 0.746 | 1.053 | 0.769-1.44 |
| Model 2                        | 0.39 | 1.162 | 0.825-1.64 |
| Lymph node metastasis          |    |      |          |
| Model 1                        | 0.019 | 1.342 | 1.049-1.72 |
| Model 2                        | 0.077 | 1.263 | 0.975-1.64 |
| Lymph node metastasis in central area |    |      |          |
| Model 1                        | 0.018 | 0.735 | 0.569-0.95 |
| Model 2                        | 0.04 | 1.317 | 1.012-1.72 |
| Stage 3/4                      |    |      |          |
| Model 1                        | 0.836 | 0.918 | 0.408-2.065 |
| Model 2                        | 0.261 | 1.863 | 0.629-5.52 |
| Extrathyroidal invasion        |    |      |          |
| Model 1                        | 0.982 | 1.004 | 0.727-1.38 |
| Model 2                        | 0.734 | 1.062 | 0.752-1.50 |

Model 1 showed unadjusted ORs; Model 2 was adjusted for sex, age, BMI and TSH.

Table 5: Multivariate logistic regression analysis for various prognostic factors in relation to vitamin D deficiency

|                                | P  | OR   | CI       |
|--------------------------------|----|------|----------|
| Male                           | 0 | 0.483 | 0.349-0.669 |
| Age (years)                    | 0 | 0.959 | 0.947-0.972 |
| TSH (mU/L)                     | 0.062 | 0.97 | 0.939-1.002 |
| Tumor size (mm)                | 0.016 | 1.022 | 1.004-1.041 |
| Central lymph node metastasis  | 0.026 | 1.428 | 1.043-1.954 |
4. Discussion

Papillary thyroid cancer is often an indolent disease, but it can become much more aggressive in its advanced stages. The 5-year survival rate of stage 1 and 2 thyroid papillary carcinoma is close to 100%, while that of stage 4 thyroid papillary carcinoma decreased to 51% [15]. Increasing tumor size, lymph node metastasis and extra-thyroid invasion have been found as poor prognostic factors for papillary thyroid cancer [16, 17].

Vitamin D and its metabolites were found to be capable of regulating cell differentiation and proliferation of normal and malignant cells [18]. The relationship between vitamin D level and thyroid disease has been highlighted recently. It was first observed in 2010 that impaired vitamin D metabolism implicated in thyroid follicular cell oncogenesis by Stepien, Tomasz et al [19]. They found a significant decrease in circulating 1-25 (OH) 2 D 3 concentrations in patients with different TNM stage and histological subtypes. These findings were supported by several studies performed subsequently [7, 8, 9].

However, the exact mechanisms have not been known yet. The promotion actions of vitamin D deficiency on immunological reaction might be the mechanism
involved. Thyroid cancer often shows inflammatory cell infiltration [20, 21, 22], inflammatory cells possess pro-tumorigenic potential, the oncoprotein can trigger the pro-inflammatory process in turns [23]. Therefore, the inflammatory process may provide a potential explanation for the underlying association between low vitamin D status and advanced papillary thyroid cancer.

In this study, we observed a negative linear correlation between tumor size and 25(OH)D level, tumor size increased with decreased 25(OH)D level. Besides, we found that VDD was significantly correlated with increased tumor size and central lymph node metastasis, independent of age, sex, BMI and TSH. The results of our study indicated that VDD was an independent risk factor for advanced papillary thyroid cancer.

Similar conclusions had been reached by Kim, Ji Ryang et al [24]. They reported that patients with tumor size \( \geq 1 \text{cm} \) (\( p = 0.041 \)) or lymph node metastasis had a significantly lower preoperative 25(OH) D level (\( p = 0.043 \)), and there was a linear correlation between preoperative vitamin D levels and tumor size. But the study was only performed on 548 female patients, and the absence of male patients could lead to different outcomes. Another retrospective study involved 820 cases of papillary thyroid cancer further analyzed the relationship between vitamin D quartiles and poor prognostic factors including extra-thyroid invasion, lymph node metastasis, advanced cancer stage (stage III or IV) and recurrence risk. But they failed to demonstrate a significant association between 25(OH)D level and thyroid cancer [25]. Sulibhavi, Anita et al [26] had identified that vitamin D deficiency correlated with thyroid cancer stage, but only limited to those who documented Vitamin D deficiency, and the laboratory values examined before surgery did not show a significant correlation. There had been another article reported similar results and the different distribution of vitamin D levels in benign and malignant thyroid tumors [19]. However, the number of patients involved in the study was too small to draw strong conclusions.

An additional finding in our study was that preoperative 25(OH)D level was significantly correlated with preoperative TSH, but this relationship was not significant after surgery. Q.Zhang et al [27] had the same conclusions, while others had conflicting results [28]. In a cross-sectional cohort study, increased TSH level was found to association with the risk of cancer in thyroid nodules and had an impact on prognosis. However, no correlation was found between 25(OH)D level and thyroid carcinoma, or TSH level [29]. Therefore, in our study, TSH was also listed as a potential confounding factor in regression analysis.
There were some experimental evidence supported the claim that vitamin D reduces the risk of cancer incidence and death [4, 30]. A recent study evaluated whether vitamin D receptor can be used as a cancer treatment target for poorly differentiated thyroid cancer. They found promising results, although it depended on the specific genotype of the vitamin D receptor [31]. Another case has been reported in which vitamin D3 (cholecalciferol) being used as a therapeutic measure to halt progression of advanced cases of thyroid cancer [32].

In conclusion, 25(OH)D level was significantly associated with certain poor prognosis factors of papillary thyroid cancer. Assessing and supplementing vitamin D may be an important addition to preoperative management of patients with papillary thyroid cancer. Further prospective investigations on vitamin D supplementation for patients with papillary thyroid cancer before surgery using larger cohorts are need.

Declarations:

Funding and Conflicts of interests

The authors did not receive support from any organization for the submitted work. The authors have no relevant financial or non-financial interests to disclose.

Ethics approval

Ethical approval was waived by the local Ethics Committee of West China Hospital, Sichuan University, in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.

References

[1] M. Soilu-Hänninen, M. Laaksonen, I. Laitinen, J. P. Erälinna, E. M. Liljus, I. Mononen, A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis, Journal of Neurology, Neurosurgery and Psychiatry 79 (1) (2008) 152–157. doi:10.1136/jnnp.2006.105320
[2] J. Y. Tang, E. H. Epstein, Vitamin D and skin cancer, 2011. doi:10.1016/B978-0-12-381978-9.10089-7.

[3] D. M. Freedman, S. C. Chang, R. T. Falk, M. P. Purdue, W. Y. Huang, C. A. McCarty, B. W. Hollis, B. Graubard, C. D. Berg, R. G. Ziegler, Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial, Cancer Epidemiology Biomarkers and Prevention 17 (4) (2008) 889–894. doi:10.1158/1055-9965.EPI-07-2594.

[4] W. B. Grant, Review of recent advances in understanding the role of Vitamin D in reducing cancer risk: Breast, colorectal, prostate, and overall cancer, Anticancer Research 40 (1) (2020) 491–499. doi:10.21873/anticanres.13977.

[5] D. S. Dean, I. D. Hay, Prognostic indicators in differentiated thyroid carcinoma, Cancer Control 7 (3) (2000) 229–239. doi:10.1177/107327480000700302.

[6] D. K. Panda, D. Miao, M. L. Tremblay, J. Sirois, R. Farookhi, G. N. Hendy, D. Goltzman, Targeted ablation of the 25-hydroxyvitamin D 1α-hydroxylase enzyme: Evidence for skeletal, reproductive, and immune dysfunction, Proceedings of the National Academy of Sciences of the United States of America 98 (13) (2001) 7498–7503. doi:10.1073/pnas.131029498.

[7] M. Penna-Martinez, E. Ramos-Lopez, J. Stern, H. Kahles, N. Hinsch, M. L. Hansmann, I. Selkinski, F. Grünwald, C. Vorländer, W. O. Bechstein, S. Zeuzem, K. Holzer, K. Badenhoop, Impaired vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma, Thyroid 22 (7) (2012) 709–716. doi:10.1089/thy.2011.0330.

[8] M. J. Hu, Q. S. Niu, H. B. Wu, X. L. Lu, L. Wang, X. R. Tong, F. Huang, Association of thyroid cancer risk with plasma 25-hydroxyvitamin D and vitamin D binding protein: a case–control study in China, Journal of Endocrinological Investigation 43 (6) (2020) 799–808. doi:10.1007/s40618-019-01167-7.

[9] D. D. Bikle, J. Schwartz, Vitamin D binding protein, total and free Vitamin D levels in different physiological and pathophysiological conditions, Frontiers in Endocrinology 10 (MAY) (2019) 1–12. doi:10.3389/fendo.2019.00317.

[10] W. Ke, T. Sun, Y. Zhang, L. He, Q. Wu, J. Liu, B. Zha, 25-hydroxyvitamin D serum level in Hashimoto’s thyroiditis, but not Graves’ disease is relatively deficient, Endocrine Journal 64 (6) (2017) 581–587. doi:10.1507/endocrj.EJ16-0547.
[11] M. M. Calapkulu, M. E. Sencar, D. Sakiz, I. O. Unsal, M. Ozbek, E. Cakal, The importance of vitamin D level in subacute thyroiditis disease and the effect of vitamin D on disease prognosis, Endocrine Practice 26 (10) (2020) 1062–1069. doi:10.4158/EP-2020-0046.

[12] C. J. Heisel, A. L. Riddering, C. A. Andrews, A. Kahana, Serum Vitamin D Deficiency Is an Independent Risk Factor for Thyroid Eye Disease, Ophthalmic Plastic and Reconstructive Surgery 36 (1) (2020) 17–20. doi:10.1097/IOP.0000000000001437.

[13] N. D. Perrier, J. D. Brierley, R. M. Tuttle, Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA: A Cancer Journal for Clinicians 68 (1) (2018) 55–63. doi:10.3322/caac.21439.

[14] M. F. Holick, N. C. Binkley, H. A. Bischoff-Ferrari, C. M. Gordon, D. A. Hanley, R. P. Heaney, M. H. Murad, C. M. Weaver, Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline, Journal of Clinical Endocrinology and Metabolism 96 (7) (2011) 1911–1930. doi:10.1210/jc.2011-0385.

[15] S. B. Edge, C. C. Compton, The american joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM (2010). doi:10.1245/s10434-010-0985-4.

[16] S. H. Nam, J. L. Roh, G. Gong, K. J. Cho, S. H. Choi, S. Y. Nam, S. Y. Kim, Nod al Factors Predictive of Recurrence after Thyroidectomy and Neck Dissection for Papillary Thyroid Carcinoma, Thyroid 28 (1) (2018) 88–95. doi:10.1089/thy.2017.0334.

[17] S. L. Gillanders, J. P. O’Neill, Prognostic markers in well differentiated papillary and follicular thyroid cancer (WDTC), European Journal of Surgical Oncology 44 (3) (2018) 286–296. doi:10.1016/j.ejso.2017.07.013 URL http://dx.doi.org/10.1016/j.ejso.2017.07.013.

[18] A. Verstuyf, G. Carmeliet, R. Bouillon, C. Mathieu, Vitamin D: A pleiotropic hormone, Kidney International 78 (2) (2010) 140–145. doi:10.1038/ki.2010.17 URL http://dx.doi.org/10.1038/ki.2010.17.
[19] T. Stepien, R. Krupinski, J. Sopinski, K. Kuzdak, J. Komorowski, H. Lawnicka, H. Stepien, Decreased 1-25 Dihydroxyvitamin D 3 Concentration in Peripheral Blood Serum of Patients with Thyroid Cancer, Archives of Medical Research 41 (3) (2010) 190–194. doi:10.1016/j.arcmed.2010.04.004. URL http://dx.doi.org/10.1016/j.arcmed.2010.04.004.

[20] M. Muzza, D. Degl’Innocenti, C. Colombo, M. Perrino, E. Ravasi, S. Rossi, V. Cirello, P. Beck-Peccoz, M. G. Borrello, L. Fugazzola, The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: Clinical and molecular studies, Clinical Endocrinology 72 (5) (2010) 702–708. doi:10.1111/j.1365-2265.2009.03699.x.

[21] E. Laird, H. McNulty, M. Ward, L. Hoey, E. McSorley, J. M. Wallace, E. Carson, A. M. Molloy, M. Healy, M. C. Casey, C. Cunningham, J. J. Strain, Vitamin D deficiency is associated with inflammation in older irish adults, Journal of Clinical Endocrinology and Metabolism 99 (5) (2014) 1807–1815. doi:10.1210/jc.2013-3507.

[22] M. Zanetti, S. S. Harris, B. Dawson-Hughes, Ability of vitamin D to reduce inflammation in adults without acute illness, Nutrition Reviews 72 (2) (2014) 95–98. doi:10.1111/nure.12096.

[23] A. Sica, P. Allavena, A. Mantovani, Cancer related inflammation: The macrophage connection, Cancer Letters 267 (2) (2008) 204–215. doi:10.1016/j.canlet.2008.03.028.

[24] J. R. Kim, B. H. Kim, S. M. Kim, M. Y. Oh, W. J. Kim, Y. K. Jeon, S. S. Kim, B. J. Lee, Y. K. Kim, I. J. Kim, Low serum 25 hydroxyvitamin d poor clinicopathis associated with ologic characteristics in female patients with papillary thyroid cancer, Thyroid 24 (11) (2014) 1618–1624. doi:10.1089/thy.2014.0090.

[25] H. Y. Ahn, Y. J. Chung, K. Y. Park, B. Y. Cho, Serum 25-Hydroxyvitamin D Level does not affect the aggressiveness and prognosis of papillary thyroid cancer, Thyroid 26 (3) (2016) 429–433. doi:10.1089/thy.2015.0516.

[26] A. Sulibhavi, M. L. Rohlfing, S. M. Jalisi, D. B. McAneny, G. M. Doherty, M. F. Holick, J. P. Noordzij, Vitamin D deficiency and its relationship to cancer stage in patients who underwent thyroidectomy for papillary thyroid carcinoma, American Journal of Otolaryngology - Head and Neck Medicine and Surgery 40 (4) (2019) 536–541. doi:10.1016/j.amjoto.2019.04.013.
[27] Q. Zhang, Z. Wang, M. Sun, M. Cao, Z. Zhu, Q. Fu, Y. Gao, J. Mao, Y. Li, Y. Shi, F. Yang, S. Zheng, W. Tang, Y. Duan, X. Huang, W. He, T. Yang, Association of high vitamin D status with low circulating thyroid-stimulating hormone independent of thyroid hormone levels in middle-aged and elderly males, International Journal of Endocrinology 2014. doi:10.1155/2014/631819.

[28] P. Zhou, J. Cai, M. Markowitz, Absence of a relationship between thyroid hormones and Vitamin D levels, Journal of Pediatric Endocrinology and Metabolism 29 (6) (2016) 703–707. doi:10.1515/jpem-2015-0210.

[29] D. L. S. Danilovic, B. Ferraz-de Souza, A. W. Fabri, N. O. Santana, M. A. Kulcsar, C. R. Cernea, S. Marui, A. O. Hoff, 25-Hydroxyvitamin D and TSH as risk factors or prognostic markers in thyroid carcinoma, PLoS ONE 11 (10) (2016) 1–12. doi:10.1371/journal.pone.0164550.

[30] X. Zhang, Y. J. Fang, X. L. Feng, A. Abulimiti, C. Y. Huang, H. Luo, N. Q. Zhang, Y. M. Chen, C. X. Zhang, Higher intakes of dietary vitamin D, calcium and dairy products are inversely associated with the risk of colorectal cancer: A case-control study in China, British Journal of Nutrition 123 (6) (2020) 699–711. doi:10.1017/S000711451900326X.

[31] V. Sharma, D. Fretwell, Z. Crees, A. Kerege, J. P. Klopper, Thyroid cancer resistance to vitamin D receptor activation is associated with 24-hydroxylase levels but not the ff FokI polymorphism, Thyroid 20 (10) (2010) 1103–1111. doi:10.1089/thy.2010.0096.

[32] M. Morishita, A. Ohtsuru, A. Kumagai, H. Namba, N. Sato, T. Hayashi, S. Yamashita, Vitamin D3 treatment for locally advanced thyroid cancer: A case report, Endocrine Journal 52 (5) (2005) 613–616. doi:10.1507/endocrj.52.613.
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- elsarticlenum.pdf
- model1numnames.pdf
- model2names.pdf
- elsarticlenum.bst
- model1numnames.bst
- model1anumnames.bst
- model2names.bst
- model3numnames.bst
- model4names.bst
- model5names.bst
- mybibfile.bib
- model6numnames.bst
- numcompress.sty